Human platelets express authentic CB1 and CB2 receptors

Current Neurovascular Research

Volumn 7, Issue 4, 2010, Pages 311-318

  Catani, M V ^a   Gasperi, V ^a   Catanzaro, G ^b,c   Baldassarri, S ^d   Bertoni, A ^d   Sinigaglia, F ^d   Avigliano, L ^a   MacCarrone, M ^b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

2 arachidonoylglycerol; Anandamide; Cannabinoid receptor type 1; Cannabinoid receptor type 2; Human platelets; Neurovascular disease

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR;

ADULT; ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THROMBOCYTE; WESTERN BLOTTING;

EID: 78650667422     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720210793180774     Document Type: Article

References (59)

1. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002; 25(10): 899-904.
2. Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9(1): 61-7
3. Leoncini G, Signorello MG, Segantin A, et al. In retinal vein occlusion platelet response to thrombin is increased. Thromb Res 2009; 124(6): e48-55.
4. Horstman LL, Jy W, Ahn YS, et al. Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 2010; 7: 10.
5. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008; 27(5): 27.
6. Sun-Edelstein C, Mauskop A. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother 2009; 9(3): 369-79.
7. Cupini LM, Bari M, Battista N, et al. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 2006; 26(3): 277-81.
8. Greco R, Gasperi V, Maccarrone M, Tassorelli C. The endocannabinoid system and migraine. Exp Neurol 2010; 224(1): 85-91.
9. Randall MD. Endocannabinoids and the haematological system. Br J Pharmacol 2007; 152(5): 671-5.
10. Ziegelstein RC, Parakh K, Sakhuja A, Bhat U. Platelet function in patients with major depression. Intern Med J 2009; 39(1): 38-43.
11. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52(4): 601-7.
12. Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 2009; 30(1): 1-7. [13] Bátkai S, Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res 2009; 60(2): 99-106.
13. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 1997; 390(6659): 518-21.
14. Valk P, Verbakel S, Vankan Y, et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for haematopoietic cells. Blood 1997; 90(4): 1448-57.
15. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases. J Neuroimmun 2005; 166(12): 3-18.
16. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51(8): 1356-67.
17. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agrò A. Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001; 268(3): 819-25.
18. Maccarrone M, Del Principe D, Finazzi Agro A. Endocannabinoids: New physiological (co-) agonists of human platelets. Thromb Haemost 2002; 88(2): 165-6.
19. Maccarrone M, Bari M, Del Principe D, Finazzi-Agro A. Activation of human platelets by 2-arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 2003; 89(2): 340-7.
20. Malorni W, Bari M, Straface E, et al. Morphological evidence that 2-arachidonoylglycerol is a true agonist of human platelets. Thromb Haemost 2004; 92(5): 1159-61.
21. Baldassarri S, Bertoni A, Bagarotti A, et al. The endocannabinoid 2-arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. J Thromb Haemost 2008; 6(10): 1772-9.
22. Battista N, Fezza F, Maccarrone M. Endocannabinoids and their involvement in the neurovascular system. Curr Neurovasc Res 2004; 1(2): 129-40.
23. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7(5): 438-55.
24. Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol 2009; 13(3): 309-20.
25. Catani MV, Gasperi V, Evangelista D, et al. Anandamide extends platelets survival through CB(1)-dependent Akt signaling. Cell Mol Life Sci 2010; 67(4): 601-10.
26. Schäfer A, Pfrang J, Neumüller J, Fiedler S, Ertl G, Bauersachs J. The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 2008; 154(5): 1047-54.
27. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008; 14 (23): 2370-82.
28. Ramaschi G, Torti M, Festetics ET, Sinigaglia F, Malavasi F, Balduini C. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood 1996; 87(6): 2308-13.
29. Catani MV, Fezza F, Baldassarri S, et al. Expression of the endo-cannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol. J Mol Med 2009; 87(1): 65-74.
30. Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci 2007; 64(2): 219-29.
31. Pasquariello N, Catanzaro G, Marzano V, et al. Characterization of the endocannabinoid system in human neuronal cells, and proteomic analysis of anandamide-induced apoptosis. J Biol Chem 2009; 284(43): 29413-26.
32. Johannessen B, Roemer B, Flatmoen L, Just T, Aarsand AK, Scott CS. Implementation of monoclonal antibody fluorescence on the Abbott CELL-DYN Sapphire haematology analyser: evaluation of lymphoid, myeloid and platelet markers. Clin Lab Haematol 2006; 28(2): 84-96.
33. Grimsey NL, Goodfellow CE, Scotter EL, Dowie MJ, Glass M, Graham ES. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods 2008; 171(1): 78-86. [35] Wager-Miller J, Westenbroek R, Mackie K. Dimerization of G-protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 2002; 121(1-2): 83-9.
34. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284): 561-4.
35. Song C, Howlett AC. Rat brain cannabinoid receptors are N-linked glycosylated proteins. Life Sci 1995; 56(2324): 1983-89.
36. López de Jesus M, Sallés J, Meana JJ, Callado LF. Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. Neuroscience 2006; 140(2): 635-43.
37. Porcella A, Maxia C, Gessa GL, Pani L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci 2000; 12(3): 1123-7.
38. Yang ZM, Paria BC, Dey SK. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development. Biol Reprod 1996; 55(4): 756-61.
39. Dove Pettit A, Harrison MP, Olson JM, Spencer RF, Cabral GA. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 1998; 51(3): 391-402.
40. Howlett AC, Champion-Dorow TM, McMahon LL, Westlake TM. The cannabinoid receptor: biochemical and cellular properties in neuroblastoma cells. Pharmacol Biochem Behav 1991; 40(3): 565-9.
41. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129-80.
42. Gómez del Pulgar, T., Velasco, G. and Guzmán, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000; 47(Pt 2): 369-73.
43. Viscomi MT, Oddi S, Latini L, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009; 29(14): 4564-70.
44. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 2004; 99(4): 1127-30.
45. Smith SK, Limbird LE. Solubilization of human platelet alpha-adrenergic receptors: evidence that agonist occupancy of the receptor stabilizes receptor-effector interactions. Proc Natl Acad Sci USA 1981; 78(7): 4026-30.
46. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 2004; 279(34): 36013-21.
47. Brusco A, Tagliaferro PA, Saez T, Onaivi ES. Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci 2008; 1139: 450-7.
48. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310(5746): 329-32.
49. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071(1): 10-23. (Pubitemid 43255471)
50. Currie S, Rainbow RD, Ewart MA, et al. IP(3)R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol 2008; 45(6): 804-11.
51. Maccarrone M, Fiori A, Bari M, et al. Regulation by cannabinoid receptors of anandamide transport across the blood-brain barrier and through other endothelial cells. Thromb Haemost 2006; 95(1): 117-27.
52. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2008; 64(1): 1-8.
53. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsycho-pharmacology 2007; 32(6): 1384-90.
54. Palmar M, Marcano A, Castejon O. Fine structural alterations of blood platelets in depression. Biol Psychiatry 1997; 42(10): 965-68.
55. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60(6): 2319-22.
56. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368(9548): 1660-72.
57. Wang H, Dey SK, Maccarrone M. Jekyll and Hyde: Two faces of cannabinoid signaling in male and female fertility. Endocr Rev 2006; 27(5): 427-48.
58. Wright KL, Robertson DA, Moyer MP, Ward SG. Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer. Int J Cancer 2008; 122(8): 1920-21.
59. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: New hopes, old concerns? Arterioscler Thromb Vasc Biol 2009; 29(1): 7-9.